• Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Home
  • About Us
  • Blog
  • Subscribe to the Journal
  • Contact Us
Sleep Diagnosis and Therapy

Sleep Diagnosis and Therapy

Official Publication of the American Sleep and Breathing Academy

Vanda Pharma 1Q Loss on Sleep Disorder Drug Costs

May 9, 2012 by admin

Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA),. said Tuesday it took a loss in the first quarter as it spent more money developing its sleep disorder drug tasimelteon.

Vanda said over the first three months of the year it lost $8 million, or 28 cents per share. A year ago it reported a profit of $136,000, which was break-even on a per-share basis. Its revenue rose to $8.1 million from $7.5 million.

The company said its research and development costs nearly tripled to $12.2 million from $4.3 million as it studied tasimelteon as a treatment for sleep disorders in people who are blind. Vanda said it expects to finish two late-stage trials of tasimelteon by the end of 2012 and file for marketing approval of the drug in mid-2013.

Key Highlights:

  • The tasimelteon Non-24-Hour Disorder (Non-24) program continues to advance towards the goal of a projected mid-2013 New Drug Application (NDA) filing with the U.S. Food and Drug Administration(FDA).  Vanda expects to complete the two Phase III efficacy studies, SET and RESET, by the end of 2012. 

  • Initial clinical data in the RESET study revealed potential of tasimelteon to reset the body clock in Non-24.  

  • The tasimelteon MAGELLAN Phase IIb/III efficacy study for Major Depressive Disorder (MDD) is ongoing and Vanda expects to report top-line results in the first half of 2013.

Source: Vanda Pharma

Filed Under: Blog

Primary Sidebar

More to See

Snoring, American Sleep and Breathing Academy and the NY Times

August 23, 2022 By admin

Jazz Pharma Presents 17 New Posters for SLEEP 2022

June 6, 2022 By admin

Tags

apnea CPAP Health Home Sleep Home Sleep Testing insomnia narcolepsy obstructive sleep apnea Sleep sleep apnea sleep apnea symptoms sleep apnea syndrome sleep apnea treatment sleep appliances sleep buisness Sleep Business sleep center Sleep Centers sleep community sleep diagnosis sleep diagnostic sleep diagnostics sleep disease sleep disorder sleep disorder center sleep disordered breathing sleep disorders sleep heart health sleep industry sleeping Sleep Lab sleep labs sleep management sleep medicine sleep monitor sleep physicians sleep problems sleep studies sleep study sleep technologist sleep test sleep testing Technology therapy Treatment

Footer

About SleepDT

SleepDT Sleep Diagnosis and Therapy is a clinical Journal for allied Sleep Professionals, Neurologists, Psychiatrists, Pulmonologists, Primary Care Physicians, and other medical specialists. We also advocate on behalf of patient care in the field of Sleep Medicine

Recent

  • SUPPORT AND PROMOTE DENTAL SLEEP MEDICINE IN 2023!
  • Snoring, American Sleep and Breathing Academy and the NY Times
  • Jazz Pharma Presents 17 New Posters for SLEEP 2022
  • AJMC Hypes SLEEP 2022
  • Avadel Pharmaceuticals’ Stock Falls

NAVIGATION

  • Home
  • About Us
  • Blog
  • Subscribe to the Journal
  • Contact Us

Copyright © 2023 · Sleep Diagnosis and Therapy